Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) — Cash Flow Reinvestment Rate
Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has a Cash Flow Reinvestment Rate of 0.06x as of September 2025, reinvesting CN¥4.69 Million (capex CN¥4.69 Million ) from operating cash flow of CN¥76.07 Million. Check 688621 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Beijing Sun Novo Pharmaceutical Research Co Ltd Cash Flow Reinvestment Rate (2017–2025)
Historical reinvestment intensity for Beijing Sun Novo Pharmaceutical Research Co Ltd across 9 annual periods. Explore Beijing Sun Novo Pharmaceutical Research cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2025)
Year-by-year capital reinvestment analysis for Beijing Sun Novo Pharmaceutical Research Co Ltd. For live market cap and broader valuation context, see market cap of Beijing Sun Novo Pharmaceutical Research.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 2.22x | CN¥206.80 Million | CN¥93.21 Million | CN¥42.43 Million | ▲ +5.0% |
| 2024 | 2.11x | CN¥67.63 Million | CN¥32.02 Million | CN¥30.48 Million | ▲ +21.4% |
| 2023 | 1.74x | CN¥161.62 Million | CN¥92.86 Million | CN¥72.96 Million | ▲ +56.8% |
| 2022 | 1.11x | CN¥115.37 Million | CN¥103.96 Million | CN¥103.87 Million | ▼ -72.9% |
| 2021 | 4.09x | CN¥360.74 Million | CN¥88.25 Million | CN¥84.96 Million | ▲ +310.5% |
| 2020 | 1.00x | CN¥62.74 Million | CN¥62.99 Million | CN¥27.03 Million | ▲ +39.0% |
| 2019 | 0.72x | CN¥40.83 Million | CN¥56.97 Million | CN¥25.67 Million | ▲ +92.6% |
| 2018 | 0.37x | CN¥16.41 Million | CN¥44.11 Million | CN¥16.41 Million | ▼ -85.8% |
| 2017 | 2.62x | CN¥20.96 Million | CN¥8.01 Million | CN¥20.96 Million | — |